Omeros is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system and immune-related diseases, including cancers. The company's drug product OMIDRIA? is marketed in the U.S. for use during cataract surgery or intraocular lens replacement. In its pipeline the company has clinical-stage development programs focused on: complement-associated thrombotic microangiopathies; complement-mediated glomerulonephropathies; and addictive and compulsive disorders.
  • TickerOMER
  • ISINUS6821431029
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryUnited States

Analysts

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

OMEROS CORPORATION sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of OMEROS CORPORATION (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 24, 2019, the closing price was USD 17.41 and its target price was estimated at USD 11.37.

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Liana Moussatos ...
  • Shveta Dighe

Safety and Tolerability Demonstrated in OMS527 Phase 1 Study for Addiction

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

OMEROS CORPORATION sees a downgrade to Negative on account of less fundamental stars

The independent financial analyst theScreener just lowered the general evaluation of OMEROS CORPORATION (US), active in the Biotechnology industry. As regards its fundamental valuation, the title now shows 1 out of 4 stars while market behaviour can be considered risky. theScreener believes that the title remains under pressure due to the loss of a star(s) and downgrades its general evaluation to Negative. As of the analysis date September 24, 2019, the closing price was USD 17.41 and its target price was estimated at USD 11.37.

ValuEngine Rating and Forecast Report for OMER

ValuEngine Rating and Forecast Report for OMER

ResearchPool Subscriptions

Get the most out of your insights

Get in touch